Clinical trials: Stomach Ulcer
Reflux Oesophagitis
Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers
The objectives of this study were: To compare repeated doses of YF476 at 2 dose levels, placebo and omeprazole with respect to their effect on basal- and food- stimulated gastric pH in healthy volunteers.
- Trial name
- NCT01599858
- Testing
- YF476, Omeprazole
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Reflux Esophagitis
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.
- Trial name
- NCT05813561
- Testing
- DWP14012
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Acute Gastritis, Gastric Ulcer
Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer
This is a self-controlled, open, multiple-center clinical trial.
- Trial name
- NCT01190657
- Testing
- Selbex
- Where
- 26 sites in China
- Volunteers
- 1,184 people
- Sponsor
- Eisai Co., Ltd.
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Initial Treatment)
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by…
- Trial name
- NCT00633932
- Testing
- Esomeprazole, Omeprazole
- Where
- 41 sites in Japan
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
Erosive Esophagitis, Reflux Esophagitis
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.
- Conditions
- Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
- Trial name
- NCT00206180
- Testing
- esomeprazole magnesium (oral medication)
- Where
- 39 sites in United States
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.
Reflux Esophagitis (RE)
A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.
- Trial name
- NCT07010107
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Duodenal Ulcer
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)
Patients with endoscopically diagnosed active duodenal ulcer disease were enrolled in a randomized, double-blind, parallel and dose-ranging trial.
- Trial name
- NCT00953381
- Testing
- 5 mg ilaprazole, 10 mg ilaprazole, 20 mg ilaprazole
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
NSAID Associated Gastric Ulcers
Prevention of Gastric Ulcers
Nonsteroidal anti-inflammatory drugs (NSAIDS) are often associated with gastric ulcers. This study looks at the prevention of these gastric ulcers with one of the three following treatment groups for up to 8 weeks: esomeprazole…
- Trial name
- NCT00629512
- Testing
- Esomeprazole
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer
Nexium Capsules LDA Specific Clinical Experience Investigation
The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose…
- Trial name
- NCT01729182
- Where
- 47 sites in Japan
- Volunteers
- 2,363 people
- Sponsor
- AstraZeneca
Stomach Ulcer, Duodenal Ulcer
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
The purpose of this study is to determine whether lansoprazole, once daily (QD), compared to gefarnate, twice daily (BID), is effective in preventing the recurrence of gastric and duodenal ulcers in patients receiving long term…
- Trial name
- NCT00762359
- Testing
- Lansoprazole, Gefarnate
- Where
- 65 sites in Japan
- Volunteers
- 461 people
- Sponsor
- Takeda
Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
The purpose of this survey is to evaluate the safety and effectiveness of vonoprazan tablets in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in the routine clinical setting.
- Trial name
- NCT03214952
- Testing
- Vonoprazan
- Where
- Japan
- Volunteers
- 3,183 people
- Sponsor
- Takeda
Refractory Reflux Esophagitis
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis
- Trial name
- NCT01321567
- Testing
- rabeprazole sodium
- Where
- 447 sites in Japan
- Volunteers
- 2,157 people
- Sponsor
- Eisai Co., Ltd.
Gastric Ulcer
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec
This randomized, double-blind, parallel-group, controlled, multi-center clinical trial of 6 months duration is designed to assess the efficacy, tolerability and safety of PN400 versus diclofenac/misoprostol in subjects at high…
- Trial name
- NCT00594854
- Testing
- PN400 (VIMOVO), Diclofenac/Misoprostol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- POZEN
Gastric Ulcer, Duodenal Ulcer
Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)
The purpose of this study is to compare the effect of esomeprazole 20 or 40 mg once daily versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid.
- Trial name
- Oberon (NCT00441727)
- Testing
- Esomeprazole 40 mg, Esomeprazole 20 mg
- Where
- 189 sites in United States, Argentina and 18 more
- Volunteers
- 2,426 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer
BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects
The purpose of this study is; To investigate whether a D961H sachet 20 mg is bioequivalent to a D961H HPMC capsule 20 mg by the assessment of percentage of time with intragastric pH>4.
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Esophagitis
- Trial name
- NCT01964131
- Testing
- D961H sachet 20 mg, D961H HPMC capsule 20 mg
- Where
- 2 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Peptic Ulcer
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
To assess the efficacy and safety of the early administration of somatostatin in infusion during 72 hours plus 2 boluses, compared to placebo in the control of acute severe UGIB with suspicion of PUB.
- Trial name
- NCT00152399
- Testing
- Somatostatin UCB (drug)
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 370 people
- Sponsor
- UCB Pharma
Stomach Ulcer, Duodenal Ulcer
Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs
The purpose of this study is to determine whether AG-1749 (lansoprazole), once daily (QD), is effective in preventing the recurrence of gastric and duodenal ulcers in patients receiving long term treatment with nonsteroid…
- Trial name
- NCT00787254
- Testing
- Lansoprazole, Gefarnate
- Where
- 68 sites in Japan
- Volunteers
- 366 people
- Sponsor
- Takeda
Zollinger-Ellison Syndrome
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.
- Trial name
- NCT00079833
- Testing
- Esomeprazole magnesium (Nexium)
- Where
- 8 sites in United States, France
- Volunteers
- 25 people
- Sponsor
- AstraZeneca